A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Recruiting

Phase 1

Phase 2

PF-08634404 with Sigvotatug VedotinA Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Sponsor:

Pfizer

Code:

NCT07227298

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-08634404

Sigvotatug Vedotin

Combination Agent 1

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-08. This information was provided to ClinicalTrials.gov by Pfizer on 2026-03-02.